Free Trial
NASDAQ:ADVM

Adverum Biotechnologies Q2 2025 Earnings Report

Adverum Biotechnologies logo
$4.06 +0.60 (+17.34%)
Closing price 09/23/2025 04:00 PM Eastern
Extended Trading
$4.11 +0.05 (+1.11%)
As of 09:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adverum Biotechnologies EPS Results

Actual EPS
-$2.34
Consensus EPS
-$2.24
Beat/Miss
Missed by -$0.10
One Year Ago EPS
N/A

Adverum Biotechnologies Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Adverum Biotechnologies Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 12, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Adverum Biotechnologies' Q3 2025 earnings is scheduled for Monday, November 3, 2025, with a conference call scheduled on Friday, November 7, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Adverum Biotechnologies Earnings Headlines

Forget AI Stocks — This Device Will REPLACE the Microchip
While everyone's chasing the same AI plays, George Gilder is focused on something completely different. He says a 4-nanometer device that's 80 MILLION times more powerful than the chip he gave Reagan is now being made in America for the first time. And he's identified 3 companies that control this technology.tc pixel
See More Adverum Biotechnologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adverum Biotechnologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adverum Biotechnologies and other key companies, straight to your email.

About Adverum Biotechnologies

Adverum Biotechnologies (NASDAQ:ADVM) is a clinical-stage gene therapy company focused on the discovery, development and delivery of novel treatments for ocular and rare diseases. Utilizing adeno-associated virus (AAV)–based vectors, the company seeks to deliver long-lasting, one-time therapies designed to address underlying genetic causes of vision loss and other conditions. Its proprietary platform combines engineering of AAV capsids for targeted tissue tropism with optimized expression cassettes, aiming to improve safety and durability over current standards of care.

The company’s lead programs target retinal disorders, including wet age-related macular degeneration (wet AMD) and diabetic retinopathy, through intravitreal administration of AAV vectors expressing therapeutic proteins. Key pipeline candidates include ADVM-022, which delivers a gene encoding an anti-VEGF molecule, and ADVM-043, a next-generation vector designed for broad ocular neovascular indications. Preclinical efforts also explore additional ophthalmic and rare disease targets, leveraging Adverum’s vector design expertise to expand into conditions with significant unmet medical need.

Adverum conducts research and clinical development primarily in the United States, with trial sites and regulatory engagement extending into Europe and other regions. The company collaborates with academic institutions, contract research organizations and strategic partners to advance its programs through Phase 1 and Phase 2 studies. Manufacturing and supply chain activities are supported by external GMP-compliant facilities, enabling scalable vector production for both clinical and future commercial use.

Founded in 2006 (formerly known as Avalanche Biotechnologies), Adverum Biotechnologies has evolved through multiple financing rounds and a 2019 corporate rebranding to reflect its broadened gene therapy ambitions. The company is led by President and Chief Executive Officer Adie Kim, whose background in specialty pharmaceuticals and biotech supports Adverum’s transition from early research to late-stage clinical development. Through its focused platform and strategic collaborations, Adverum aims to deliver durable, potentially curative treatments that could transform care for patients with vision disorders and other genetic diseases.

View Adverum Biotechnologies Profile

More Earnings Resources from MarketBeat